Inhibitors of LexA Autoproteolysis and the Bacterial SOS Response Discovered by an Academic-Industry Partnership

ACS Infectious Diseases

Volumn 4, Issue 3, 2018, Pages 349-359

  Mo, Charlie Y ^a,c   Culyba, Matthew J ^a,d   Selwood, Trevor ^a   Kubiak, Jeffrey M ^a   Hostetler, Zachary M ^a   Jurewicz, Anthony J ^b   Keller, Paul M ^b   Pope, Andrew J ^b   Quinn, Amy ^b   Schneck, Jessica ^b   Widdowson, Katherine L ^b   Kohli, Rahul M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEXA PROTEIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; LEXA PROTEIN, BACTERIA; PROTEINASE INHIBITOR; SERINE PROTEINASE;

ARTICLE; CELL ASSAY; FLUORESCENCE POLARIZATION; FOLLOW UP; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SOS RESPONSE (GENETICS); BACTERIUM; DRUG DEVELOPMENT; DRUG EFFECT; HIGH THROUGHPUT SCREENING; INTERSECTORAL COLLABORATION; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; METABOLISM; ORGANIZATION AND MANAGEMENT;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; INTERSECTORAL COLLABORATION; PROTEASE INHIBITORS; PROTEOLYSIS; SERINE ENDOPEPTIDASES; SOS RESPONSE (GENETICS);

EID: 85043486685     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.7b00122     Document Type: Article

References (53)

1. Radman, M. (1975) SOS repair hypothesis: Phenomenology of an inducible DNA repair which is accompanied by mutagenesis. Basic Life Sci. 5A 355-367, 10.1007/978-1-4684-2895-7-48
2. Butala, M., Zgur-Bertok, D., and Busby, S. J. (2009) The bacterial LexA transcriptional repressor. Cell. Mol. Life Sci. 66, 82-93, 10.1007/s00018-008-8378-6
3. Schlacher, K. and Goodman, M. F. (2007) Lessons from 50 years of SOS DNA-damage-induced mutagenesis. Nat. Rev. Mol. Cell Biol. 8, 587-594, 10.1038/nrm2198
4. Culyba, M. J., Mo, C. Y., and Kohli, R. M. (2015) Targets for combating the evolution of acquired antibiotic resistance. Biochemistry 54, 3573-3582, 10.1021/acs.biochem.5b00109
5. Cirz, R. T. and Romesberg, F. E. (2007) (2007) Controlling mutation: Intervening in evolution as a therapeutic strategy. Crit. Rev. Biochem. Mol. Biol. 42, 341-354, 10.1080/10409230701597741
6. Kohanski, M. A., Dwyer, D. J., and Collins, J. J. (2010) How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8, 423-435, 10.1038/nrmicro2333
7. Cirz, R. T., Chin, J. K., Andes, D. R., de Crecy-Lagard, V., Craig, W. A., and Romesberg, F. E. (2005) Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3, e176, 10.1371/journal.pbio.0030176
8. Mo, C. Y., Manning, S. A., Roggiani, M., Culyba, M. J., Samuels, A. N., Sniegowski, P. D., Goulian, M., and Kohli, R. M. (2016) Systematically altering bacterial SOS activity under stress reveals therapeutic strategies for potentiating antibiotics. mSphere 1, e00163-16, 10.1128/mSphere.00163-16
9. Thi, T. D., Lopez, E., Rodriguez-Rojas, A., Rodriguez-Beltran, J., Couce, A., Guelfo, J. R., Castaneda-Garcia, A., and Blazquez, J. (2011) Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J. Antimicrob. Chemother. 66, 531-538, 10.1093/jac/dkq496
10. Kohanski, M. A., DePristo, M. A., and Collins, J. J. (2010) Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell 37, 311-320, 10.1016/j.molcel.2010.01.003
11. Lu, T. K. and Collins, J. J. (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 106, 4629-4634, 10.1073/pnas.0800442106
12. Recacha, E., Machuca, J., Diaz de Alba, P., Ramos-Guelfo, M., Docobo-Perez, F., Rodriguez-Beltran, J., Blazquez, J., Pascual, A., and Rodriguez-Martinez, J. M. (2017) Quinolone resistance reversion by targeting the SOS response. mBio 8, e00971-17, 10.1128/mBio.00971-17
13. Da Re, S., Garnier, F., Guerin, E., Campoy, S., Denis, F., and Ploy, M. C. (2009) The SOS response promotes qnrB quinolone-resistance determinant expression. EMBO Rep. 10, 929-933, 10.1038/embor.2009.99
14. Dorr, T., Lewis, K., and Vulic, M. (2009) SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet. 5, e1000760, 10.1371/journal.pgen.1000760
15. Guerin, E., Cambray, G., Sanchez-Alberola, N., Campoy, S., Erill, I., Da Re, S., Gonzalez-Zorn, B., Barbe, J., Ploy, M. C., and Mazel, D. (2009) The SOS response controls integron recombination. Science 324, 1034, 10.1126/science.1172914
16. Gotoh, H., Kasaraneni, N., Devineni, N., Dallo, S. F., and Weitao, T. (2010) SOS involvement in stress-inducible biofilm formation. Biofouling 26, 603-611, 10.1080/08927014.2010.501895
17. Wang, M., Jacoby, G. A., Mills, D. M., and Hooper, D. C. (2009) SOS regulation of qnrB expression. Antimicrob. Agents Chemother. 53, 821-823, 10.1128/AAC.00132-08
18. Alam, M. K., Alhhazmi, A., DeCoteau, J. F., Luo, Y., and Geyer, C. R. (2016) RecA inhibitors potentiate antibiotic activity and block evolution of antibiotic resistance. Cell. Chem. Biol. 23, 381-391, 10.1016/j.chembiol.2016.02.010
19. Lee, A. M., Wigle, T. J., and Singleton, S. F. (2007) A complementary pair of rapid molecular screening assays for RecA activities. Anal. Biochem. 367, 247-258, 10.1016/j.ab.2007.04.021
20. Peterson, E. J., Janzen, W. P., Kireev, D., and Singleton, S. F. (2012) High-throughput screening for RecA inhibitors using a transcreener adenosine 5′-O-diphosphate assay. Assay Drug Dev. Technol. 10, 260-268, 10.1089/adt.2011.0409
21. Sexton, J. Z., Wigle, T. J., He, Q., Hughes, M. A., Smith, G. R., Singleton, S. F., Williams, A. L., and Yeh, L. A. (2010) Novel inhibitors of E. coli RecA ATPase activity. Curr. Chem. Genomics 4, 34-42, 10.2174/1875397301004010034
22. Wigle, T. J., Sexton, J. Z., Gromova, A. V., Hadimani, M. B., Hughes, M. A., Smith, G. R., Yeh, L. A., and Singleton, S. F. (2009) Inhibitors of RecA activity discovered by high-throughput screening: Cell-permeable small molecules attenuate the SOS response in Escherichia coli. J. Biomol. Screening 14, 1092-1101, 10.1177/1087057109342126
23. Wigle, T. J., Lee, A. M., and Singleton, S. F. (2006) (2006) Conformationally selective binding of nucleotide analogues to escherichia coli RecA: A ligand-based analysis of the RecA ATP binding site. Biochemistry 45, 4502-4513, 10.1021/bi052298h
24. Bellio, P., Di Pietro, L., Mancini, A., Piovano, M., Nicoletti, M., Brisdelli, F., Tondi, D., Cendron, L., Franceschini, N., Amicosante, G., Perilli, M., and Celenza, G. (2017) SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against escherichia coli RecA protein. Phytomedicine 29, 11-18, 10.1016/j.phymed.2017.04.001
25. Huang, F., Motlekar, N. A., Burgwin, C. M., Napper, A. D., Diamond, S. L., and Mazin, A. V. (2011) Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem. Biol. 6, 628-635, 10.1021/cb100428c
26. Tralau-Stewart, C. J., Wyatt, C. A., Kleyn, D. E., and Ayad, A. (2009) Drug discovery: New models for industry-academic partnerships. Drug Discovery Today 14, 95-101, 10.1016/j.drudis.2008.10.003
27. Hall, Z. W. and Scott, C. (2001) University-industry partnership. Science 291, 553, 10.1126/science.1058411
28. Oduor, R. O., Ojo, K. K., Williams, G. P., Bertelli, F., Mills, J., Maes, L., Pryde, D. C., Parkinson, T., Van Voorhis, W. C., and Holler, T. P. (2011) Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: A public-private partnership to identify novel leads. PLoS Neglected Trop. Dis. 5, e1017, 10.1371/journal.pntd.0001017
29. Mann, J., Taylor, P. W., Dorgan, C. R., Johnson, P. D., Wilson, F. X., Vickers, R., Dale, A. G., and Neidle, S. (2015) The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: A story of an effective academic-industrial partnership. MedChemComm 6, 1420-1426, 10.1039/C5MD00238A
30. Drag, M. and Salvesen, G. S. (2010) Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discovery 9, 690-701, 10.1038/nrd3053
31. Luo, Y., Pfuetzner, R. A., Mosimann, S., Paetzel, M., Frey, E. A., Cherney, M., Kim, B., Little, J. W., and Strynadka, N. C. (2001) Crystal structure of LexA: A conformational switch for regulation of self-cleavage. Cell 106, 585-594, 10.1016/S0092-8674(01)00479-2
32. Zhang, A. P., Pigli, Y. Z., and Rice, P. A. (2010) Structure of the LexA-DNA complex and implications for SOS box measurement. Nature 466, 883-886, 10.1038/nature09200
33. Mo, C. Y., Birdwell, L. D., and Kohli, R. M. (2014) Specificity determinants for autoproteolysis of LexA, a key regulator of bacterial SOS mutagenesis. Biochemistry 53, 3158-3168, 10.1021/bi500026e
34. Slilaty, S. N., Rupley, J. A., and Little, J. W. (1986) Intramolecular cleavage of LexA and phage lambda repressors: Dependence of kinetics on repressor concentration, pH, temperature, and solvent. Biochemistry 25, 6866-6875, 10.1021/bi00370a020
35. Little, J. W. (1984) Autodigestion of lexA and phage lambda repressors. Proc. Natl. Acad. Sci. U. S. A. 81, 1375-1379, 10.1073/pnas.81.5.1375
36. Adams, S. R., Campbell, R. E., Gross, L. A., Martin, B. R., Walkup, G. K., Yao, Y., Llopis, J., and Tsien, R. Y. (2002) New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: Synthesis and biological applications. J. Am. Chem. Soc. 124, 6063-6076, 10.1021/ja017687n
37. Wigle, T. J. and Singleton, S. F. (2007) Directed molecular screening for RecA ATPase inhibitors. Bioorg. Med. Chem. Lett. 17, 3249-3253, 10.1016/j.bmcl.2007.04.013
38. Nautiyal, A., Patil, K. N., and Muniyappa, K. (2014) Suramin is a potent and selective inhibitor of mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. J. Antimicrob. Chemother. 69, 1834-1843, 10.1093/jac/dku080
39. Nok, A. J. (2003) Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human african trypanosomiasis. Parasitol. Res. 90, 71-79, 10.1007/s00436-002-0799-9
40. Albulescu, I. C., Kovacikova, K., Tas, A., Snijder, E. J., and van Hemert, M. J. (2017) Suramin inhibits zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res. 143, 230-236, 10.1016/j.antiviral.2017.04.016
41. Naviaux, R. K., Curtis, B., Li, K., Naviaux, J. C., Bright, A. T., Reiner, G. E., Westerfield, M., Goh, S., Alaynick, W. A., Wang, L., Capparelli, E. V., Adams, C., Sun, J., Jain, S., He, F., Arellano, D. A., Mash, L. E., Chukoskie, L., Lincoln, A., and Townsend, J. (2017) Low-dose suramin in autism spectrum disorder: A small, phase I/II, randomized clinical trial. Ann. Clin. Transl. Neurol. 4, 491-505, 10.1002/acn3.424
42. Zaslaver, A., Bren, A., Ronen, M., Itzkovitz, S., Kikoin, I., Shavit, S., Liebermeister, W., Surette, M. G., and Alon, U. (2006) A comprehensive library of fluorescent transcriptional reporters for Escherichia coli. Nat. Methods 3, 623-628, 10.1038/nmeth895
43. Aldrich, C., Bertozzi, C., Georg, G. I., Kiessling, L., Lindsley, C., Liotta, D., Merz, K. M., Jr, Schepartz, A., and Wang, S. (2017) The ecstasy and agony of assay interference compounds. ACS Infect. Dis. 3, 259-262, 10.1021/acsinfecdis.7b00023
44. Barreto, K., Bharathikumar, V. M., Ricardo, A., DeCoteau, J. F., Luo, Y., and Geyer, C. R. (2009) A genetic screen for isolating ″lariat″ peptide inhibitors of protein function. Chem. Biol. 16, 1148-1157, 10.1016/j.chembiol.2009.10.012
45. Roland, K. L. and Little, J. W. (1990) Reaction of LexA repressor with diisopropyl fluorophosphate. A test of the serine protease model. J. Biol. Chem. 265, 12828-12835
46. Li, H., Aneja, R., and Chaiken, I. (2013) Click chemistry in peptide-based drug design. Molecules 18, 9797-9817, 10.3390/molecules18089797
47. Flipo, M., Willand, N., Lecat-Guillet, N., Hounsou, C., Desroses, M., Leroux, F., Lens, Z., Villeret, V., Wohlkonig, A., Wintjens, R., Christophe, T., Kyoung Jeon, H., Locht, C., Brodin, P., Baulard, A. R., and Deprez, B. (2012) Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. J. Med. Chem. 55, 6391-6402, 10.1021/jm300377g
48. Renwick, M. J., Brogan, D. M., and Mossialos, E. (2016) A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J. Antibiot. 69, 73-88, 10.1038/ja.2015.98
49. Booth, B. and Zemmel, R. (2004) Prospects for productivity. Nat. Rev. Drug Discovery 3, 451-456, 10.1038/nrd1384
50. Schachter, B. (2012) Partnering with the professor. Nat. Biotechnol. 30, 944-952, 10.1038/nbt.2385
51. Dickey, S. W., Cheung, G. Y. C., and Otto, M. (2017) Different drugs for bad bugs: Antivirulence strategies in the age of antibiotic resistance. Nat. Rev. Drug Discovery 16, 457-471, 10.1038/nrd.2017.23
52. Tracy, R. B. and Kowalczykowski, S. C. (1996) In vitro selection of preferred DNA pairing sequences by the Escherichia coli RecA protein. Genes Dev. 10, 1890-1903, 10.1101/gad.10.15.1890
53. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., and Mori, H. (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: The Keio collection. Mol. Syst. Biol. 2, 2006.0008, 10.1038/msb4100050